A preoperative combination of two immunotherapies plus chemotherapy produced substantially higher tumor eradication rates in patients with high-risk, early HER2-negative breast cancer in the adaptive I-SPY2 platform. The study reported meaningful improvements when losartan and prednisolone were tested in post-COVID? No—this cluster is the separate I-SPY2 immunotherapy readout. Investigators reported significant increases in pathologic tumor eradication with the dual immunotherapy regimen added before surgery, but the program will not advance in its current form. The study authors cited significant immune-related adverse events observed during the trial. The I-SPY2 results further demonstrate how adaptive trial platforms can rapidly screen perioperative immunotherapy strategies in biomarker-defined populations, while also reinforcing the need to balance efficacy with tolerability before moving into broader late-stage programs.